XLHealth, a Baltimore-based provider of health plan solutions for Medicare beneficiaries with special needs, announced the enrollment of its 100,000th member, and it sees room for more growth despite expected Medicare Advantage cuts
XLHealth, a Baltimore-based provider of health plan solutions for Medicare beneficiaries with special needs, announced the enrollment of its 100,000th member, and it sees room for more growth despite expected Medicare Advantage cuts.
“There is going to be increasing downward price cut pressure on all plans,” says Paul Serini, executive vice president, XLHealth. “As a starting point we’ll have that same pressure. That said, most of healthcare reform is aligned with special need plans like ours.”
He says in the next two to four years, he sees tremendous opportunities for special needs plans.
“When the dust settles from healthcare reform, any MAPD (Medicare Advantage Prescription Drug) company serving a population that’s complex enough can do a better job than traditional services,” he says. “We know we can deliver better value to our members and the Medicare system for the chronically ill.”
XLHealth focuses on a largely rural, medically underserved market and targets older members. Care Improvement Plus' chronic condition special needs plan combines medical coverage - hospital and doctors' visits - with tailored Medicare Part D prescription drug coverage and care management support for Medicare beneficiaries with diabetes and heart failure.
Care Improvement Plus launched in 2006 and now serves seniors in Arkansas, Georgia, Missouri, South Carolina, Texas and 11 Maryland counties. XLHealth estimates that approximately 7 million Medicare beneficiaries across all six states are eligible to enroll in a Care Improvement Plus plan and benefit from its model of care.
Serini says the company plans to expand in 2012. It has a target list of seven more states and 170 counties.
GLP-1s Are Flipping the Script, Says Doug Long | 2024 Asembia
May 1st 2024The growth in spending on the glucagon-like peptide 1 (GLP-1) agonists is a “mega tsunami,” said Doug Long, MBA, vice president industry relations for IQVIA. The script that specialty drugs are the main drivers of U.S. drug expenditures may need some revision.
Read More
Study Reveals Patients Benefit More with Female Doctors — More Particularly Female Patients
April 30th 2024Understanding how physician sex contributes to these disparities is crucial as evidence on the impact of physician sex on clinical outcomes remains limited, especially around patient sex.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen